Does retatrutide raise heart rate?

Trial Data on Heart Rate

TRIUMPH trials reported the following heart rate changes:

Placebo

• Baseline 70 bpm
• End of trial: 70 bpm (no change)

Retatrutide 4 mg

• Baseline 72 bpm
• End of trial: 77 bpm (+5 bpm)

Retatrutide 8 mg

• Baseline 72 bpm
• End of trial: 80 bpm (+8 bpm)

Retatrutide 12 mg

• Baseline 72 bpm
• End of trial: 82 bpm (+10 bpm)

Heart rate elevation is dose-dependent, occurring during titration and stabilizing at new elevated baseline during maintenance.

Comparison to Other GLP-1 Class Drugs

• Semaglutide: 4–6 bpm increase
• Tirzepatide: 3–5 bpm increase
• Retatrutide: 5–10 bpm increase

Retatrutide has the largest heart rate effect of the class, likely due to the glucagon receptor component enhancing metabolic rate.

Why Heart Rate Increases

GLP-1 receptor effects

• Direct cardiac effects through GLP-1 receptors in cardiac tissue
• Indirect effects through increased sympathetic nervous system activity

Glucagon receptor effects (retatrutide specific)

• Increased basal metabolic rate requires higher cardiac output
• Enhanced fat oxidation increases oxygen demand
• Moderate adrenergic-like effects

Weight loss effects (indirect)

• Rapid weight loss itself can temporarily elevate heart rate
• Activity levels often increase with weight loss

Who's Most At Risk

Higher risk

• Pre-existing atrial fibrillation or flutter
• Uncontrolled hypertension
• Heart failure
• Significant coronary artery disease
• Thyroid dysfunction (hyperthyroidism)
• Anxiety disorders with tachycardia
• Other medications that elevate heart rate

Moderate risk

• Mild hypertension
• History of arrhythmia
• Older adults (65+)
• Caffeine-sensitive individuals
• High-performance athletes

Lower risk

• Healthy middle-aged adults
• Normal cardiac evaluation
• Good baseline fitness
• No arrhythmia history

Symptoms of Concerning Heart Rate Changes

• Sustained resting heart rate above 100 bpm
• New palpitations
• Fluttering or irregular heartbeat
• Chest discomfort or pressure
• Shortness of breath at rest
• Severe exercise intolerance
• Near-fainting or actual syncope
• Unexplained fatigue despite weight loss

Any of these warrant prompt cardiology evaluation, not waiting for the next scheduled appointment.

Monitoring Protocol

Baseline

• Resting heart rate (measured at rest, after 5+ minutes seated)
• Blood pressure
• Home heart rate monitoring capability (e.g., wearable device)
• ECG if clinically indicated

During titration (every 4 weeks)

• Resting heart rate check
• Blood pressure
• Symptom review

During maintenance (every 3 months)

• Heart rate and blood pressure check
• Symptom review
• Any concerning trends

When to Hold or Reduce Dose

Hold next dose and consult provider

• New palpitations
• Resting HR > 100 bpm for multiple consecutive days
• Chest pain
• Severe fatigue disproportionate to weight loss
• Near-fainting episodes

Reduce dose

• Sustained HR increase > 15 bpm from baseline
• New onset of palpitations without concerning features
• Cardiology evaluation suggests dose reduction

Discontinue

• New diagnosis of significant arrhythmia
• Heart failure exacerbation
• Cardiac decompensation of any kind
• Unexplained syncope

Heart Rate Normalization

During continued use

• Heart rate typically stabilizes at elevated but steady level
• Not continuously climbing
• Part of the new physiological baseline

After discontinuation

• Heart rate returns to pre-treatment baseline within 2–6 weeks
• Related to drug half-life and metabolic rate normalization

Cardiovascular Outcome Considerations

Net cardiovascular effect

• Semaglutide has demonstrated CV risk reduction (SELECT trial)
• Despite HR elevation, overall CV outcomes favorable due to weight loss and metabolic improvement
• Retatrutide expected similar or greater CV benefit, but awaiting long-term CV outcomes trial
• CV benefit outweighs HR concern in most patients

Combining With Other Medications

Beta blockers

• Can offset retatrutide's HR increase
• May mask signs of concerning HR changes
• Not automatically indicated but may be considered

Calcium channel blockers

• Can provide rate control
• Useful for hypertension and HR concerns combined
• Some have additional benefits for arrhythmias

ACE inhibitors / ARBs

• Don't directly affect HR
• Standard for hypertension, often appropriate
• Don't offset retatrutide's HR elevation

Exercise and Heart Rate Considerations

Exercise during retatrutide use

• Exercise heart rate elevated at any given exertion level
• Target HR zones may need adjustment
• Check recovery HR for concerning patterns
• Don't avoid exercise — continued important for weight loss and cardiac health

Maximal exercise

• Maximum HR may be unchanged or slightly reduced
• Exercise capacity typically maintained or improved as weight decreases
• Talk to provider if any concerning symptoms during exertion

Special Populations

Athletes

• Elevated HR affects training capacity initially
• Usually adapts over 4–8 weeks
• Monitor power output vs HR to detect dysfunction

Older adults

• Lower HR tolerance in general
• More frequent monitoring warranted
• Consider starting at lowest effective dose
• Cardiology consultation more often appropriate

Athletes returning from cessation

• HR returns to baseline 2–6 weeks post-stop
• Training capacity may normalize faster than weight stability
• Plan for gradual training progression post-stop

Bottom Line

Retatrutide raises heart rate by 5–10 bpm on average. This is well-tolerated in most patients and usually doesn't require intervention. Monitor for sustained increases beyond 15 bpm, new palpitations, or cardiac symptoms. Higher-risk patients (pre-existing arrhythmia, heart failure, uncontrolled hypertension) need closer monitoring and cardiology input. The overall cardiovascular benefit from weight loss and metabolic improvement typically outweighs the HR concern for most patients.

See the retatrutide guide. Related: side effects, dosage protocol.